4D Molecular Therapeutics Inc. (FDMT)
NASDAQ: FDMTHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
FDMT stock chart
Technical analysisKey statistics
All statistics- Market cap
- $576.76M
- EPS (TTM)
- -$2.70
- Dividend yield
- None
- 52-week range
- 6.96 – 16.93
- Day range
- 10.11 – 10.94
- Volume / Avg
- 690.94K / 967.00K
- Beta
- —
- Shares outstanding
- 56.38M
52-week range
FDMT stock today
4D Molecular Therapeutics (FDMT) closed at $10.23 on Nov 20, down 4.57% (-$0.49), versus the S&P 500's 3.70% decline. Shares are 39.6% below their 52-week high of $16.93, set on Aug 19, 2026 and 47.0% above the 52-week low of $6.96, in the middle of the past year's range. FDMT is up 36.4% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 5.6%.
4D Molecular Therapeutics has posted a net loss over the last twelve months (EPS of -$2.70), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About 4D Molecular Therapeutics
Company profile4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. David H. Kirn M.D.
- Headquarters
- EmeryVille, CA
- Employees
- 196
- IPO year
- 2020
- Website
- 4dmoleculartherapeutics.com
Financial highlights
Full financialsIn fiscal 2025, 4D Molecular Therapeutics generated $85.2 million in revenue, up 230194.6% from fiscal 2024. 4D Molecular Therapeutics reported a net loss of $140.1 million, compared with a loss of $160.9 million a year earlier. Operating margin was -187.2%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $85.21M | $37.00K | $20.72M | $3.13M | $18.04M |
| Growth | +230194.59% | -99.82% | +562.29% | -82.65% | +32.52% |
| Net income | $-140.11M | $-160.87M | $-100.84M | $-107.49M | $-71.32M |
| EPS (diluted) | $-2.42 | $-2.98 | $-2.58 | $-3.32 | $-2.57 |
Analyst forecast
ForecastConsensus (12 analysts)
strong_buy
Avg. price target
$28.09+174.58%
- Strong buy 2
- Buy 9
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-1.08 vs $-1.04
- Surprise
- -3.85%
FDMT news
All FDMT news- 4DMT Announces New Employment Inducement GrantsGlobeNewswire
- 4DMT Advances 4D-150 Toward Key 2027 Readouts; Q3 Net Loss Widens To $78.1 MlnNasdaqFDMT, BF.B
- 4DMT Reports Third Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming MilestonesGlobeNewswire
- Zoetis (ZTS) Q3 Earnings and Revenues Top EstimatesNasdaqZTS, FDMT
- 4DMT to Participate in Upcoming Investor ConferencesGlobeNewswire
- 4D Molecular Therapeutics, Inc. (FDMT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?NasdaqFDMT, ZTS
- 4DMT Announces New Employment Inducement GrantsGlobeNewswire
4D Molecular Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CGEMCullinan Therapeutics Inc. | 8.89 | -1.98% | $577.15M | vs FDMT |
| ENTXEntera Bio Ltd. | 3.31 | +0.76% | $575.53M | vs FDMT |
| DBVTDBV Technologies S.A. ADR | 9.02 | -4.25% | $566.82M | vs FDMT |
| SRZNSurrozen Inc. | 28.46 | -7.21% | $596.40M | vs FDMT |
| IAMIambic Therapeutics Inc. | 13.11 | -8.06% | $621.42M | vs FDMT |
| ETRAElectra Therapeutics Inc. | 8.11 | -9.28% | $509.85M | vs FDMT |
| VALNValneva SE ADR | 5.16 | -3.82% | $490.86M | vs FDMT |
| DNAGinkgo Bioworks Holdings Inc. Class A | 7.46 | -9.02% | $483.54M | vs FDMT |
Indexes, lists and sector
4D Molecular Therapeutics stock FAQ
What is 4D Molecular Therapeutics's stock price today?
FDMT last traded at $10.23 as of Nov 20, 4:00 PM EST, down 4.57% on the day. Prices are delayed at least 15 minutes.
Who is 4D Molecular Therapeutics's CEO?
Dr. David H. Kirn M.D. is the chief executive officer of 4D Molecular Therapeutics Inc., which has about 196 employees.
What is the FDMT 52-week high?
The 52-week high for FDMT is $16.93 and the 52-week low is $6.96. The stock is currently 39.6% below its high.